Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГБОУ ДПО «Пензенский институт усовершенствования врачей» Минздрава России. 440060, Россия, Пенза, ул. Стасова, д. 8а
Список исп. литературыСкрыть список 1. Андрющенко А.В. Распространенность и структура психических расстройств в общей медицине. Психические расстройства в общей медицине. 2011; 1: 14–27. / Andriushchenko A.V. Rasprostranennost' i struktura psikhicheskikh rasstroistv v obshchei meditsine. Mental Disorders in General Medicine. 2011; 1: 14–27. [in Russian] 2. Roca M, Gili M, Garcia-Garcia M et al. Prevalence and comorbidity of common mental disorders in primary care. J Affect Disord 2009; 119 (1–3): 52–8. 3. Wittchen HU, Jacobi F, Rehm J et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21 (9): 655–79. 4. Hiller W, Fichter MM. High utilizers of medical care: a crucial subgroup among somatizing patients. J Psychosom Res 2004; 56 (4): 437–43. 5. Olesen J, Gustavsson A, Svensson M et al. The economic cost of brain disorders in Europe. Eur J Neurol 2012; 19 (1): 155–62. 6. Alciati A, Atzeni F, Sgiarovello P, Sarzi-Puttini P. Somatoform disorders and rheumatic diseases: from DSM-IV to DSM-V. Reumatismo 2014; 66 (1): 98–102. 7. Häuser W, Burgmer M, Köllner V et al. Fibromyalgia syndrome as a psychosomatic disorder – diagnosis and therapy according to current evidence-based guidelines. Z Psychosom Med Psychother 2013; 59 (2): 132–52. 8. Endresen GK. Fibromyalgia: a rheumatologic diagnosis? Rheumatol Int 2007; 27 (11): 999–1004. 9. Häuser W, Henningsen P. Fibromyalgia syndrome: a somatoform disorder? Eur J Pain 2014; 18 (8): 1052–9. 10. Carville SF, Arendt-Nielsen S, Bliddal H et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008; 67 (4): 536–41. 11. Häuser W, Walitt B, Fitzcharles MA, Sommer C. Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Res Ther 2014; 16 (1): 201. 12. Nüesch E, Häuser W, Bernardy K et al. Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis 2013; 72 (6): 955–62. 13. Aragona M, Bancheri L, Perinelli D et al. Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder. Eur J Pain 2005; 9 (1): 33–8. 14. Moore RA, Derry S, Aldington D et al. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2012; 12: CD008242. 15. Turkington D, Grant JB, Ferrier IN et al. A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder. J Clin Psychiatry 2002; 63 (9): 778–81. 16. Walitt B, Urrútia G, Nishishinya MB et al. Selective serotonin reuptake inhibitors for fibromyalgia syndrome. Cochrane Database Syst Rev 2015; 6: CD011735. 17. Ford AC, Quigley EM, Lacy BE et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2014; 109 (9): 1350–65. 18. Hookway C, Buckner S, Crosland P, Longson D. Irritable bowel syndrome in adults in primary care: summary of updated NICE guidance. BMJ 2015; 350: 701. 19. Ruepert L, Quartero AO, de Wit NJ et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011; 8: CD003460. 20. Chao GQ, Zhang S. A meta-analysis of the therapeutic effects of amitriptyline for treating irritable bowel syndrome. Intern Med 2013; 52 (4): 419–24. 21. Grover M, Camilleri M. Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases. J Gastroenterol 2013; 48 (2): 177–81. 22. Rahimi R, Nikfar S, Rezaie A et al. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol 2009; 15 (13): 1548–53. 23. Shah E, Kim S, Chong K et al. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. Am J Med 2012; 125 (4): 381–93. 24. Muller JE, Wentzel I, Koen L et al. Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial. Int Clin Psychopharmacol 2008; 23 (1): 43–8. 25. Kroenke K, Messina N, Benattia I et al. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. J Clin Psychiatry 2006; 67 (1): 72–80. 26. Müller T, Mannel M, Murck H, Rahlfs VW. Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial. Psychosom Med 2004; 66 (4): 538–47. 27. Volz HP, Murck H, Kasper S, Möller HJ. St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology (Berl) 2002; 164 (3): 294–300. 28. Прибытков А.А., Савельев В.П., Кибиткина О.Е. и др. Эффективность сертралина в терапии соматоформных расстройств. Психиатрия и психофармакотерапия. 2014; 2: 36–9. / Pribytkov A.A., Savel'ev V.P., Kibitkina O.E. i dr. Effektivnost' sertralina v terapii somatoformnykh rasstroistv. Psychiatry and Psychopharmacotherapy. 2014; 2: 36–9. [in Russian] 29. Han C, Pae CU, Lee BH et al. Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: a randomized, open-label, 12-week, parallel-group trial. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32 (2): 437–44. 30. Noyes R, Happel RL, Muller BA et al. Fluvoxamine for somatoform disorders: an open trial. Gen Hosp Psychiatry 1998; 20 (6): 339–44. 31. Прибытков А.А., Еричев А.Н., Коцюбинский А.П., Юркова И.О. Вопросы терапии соматоформных расстройств: медикаментозные и психотерапевтические подходы. Соц. и клин. психиатрия. 2014; 4: 73–80. / Pribytkov A.A., Erichev A.N., Kotsiubinskii A.P., Iurkova I.O. Voprosy terapii somatoformnykh rasstroistv: medikamentoznye i psikhoterapevticheskie podkhody. Sots. i klin. psikhiatriia. 2014; 4: 73–80. [in Russian] 32. Kleinstäuber M, Witthöft M, SteffanowskiA et al. Pharmacological interventions for somatoform disorders in adults. Cochrane Database Syst Rev 2014; 11: CD010628. 33. Kroenke K. Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. Psychosom Med 2007; 69 (9): 881–8. 34. Schröder A, Fink P. Functional somatic syndromes and somatoform disorders in special psychosomatic units: organizational aspects and evidence-based treatment. Psychiatr Clin North Am 2011; 34 (3): 673–87. 35. Стаценко О.А., Дроздовский Ю.В., Краля О.В. Применение сульпирида при терапии соматоформных расстройств. Сиб. вестн. психиатрии и наркологии. 2011; 6: 62–6. / Statsenko O.A., Drozdovskii Iu.V., Kralia O.V. Primenenie sul'pirida pri terapii somatoformnykh rasstroistv. Sib. vestn. psikhiatrii i narkologii. 2011; 6: 62–6. [in Russian] 36. Decoutere L, van den Eede F, Moorkens G, Sabbe BG. Antipsychotic agents in the treatment of somatoform disorders; a review. Tijdschr Psychiatr 2011; 53 (3): 163–73. 37. Serra J. Levosulpiride in the management of functional dyspepsia and delayed gastric emptying. Gastroenterol Hepatol 2010; 33 (8): 586–90. 38. Meyers C, Vranckx C, Elgen K. Psychosomatic disorders in general practice: comparisons of treatment with flupenthixol, diazepam and sulpiride. Pharmatherapeutica 1985; 4 (4): 244–50. 39. Zitman FG, Linssen AC, Edelbroek PM, van Kempen GM. Does addition of low-dose flupentixol enhance the analgetic effects of low-dose amitriptyline in somatoform pain disorder? Pain 1991; 47 (1): 25–30. 40. Прибытков А.А., Барыльник Ю.Б., Антохин Е.Ю. и др. Терапия соматоформных расстройств: данные исследований и повседневная практика. Психиатрия и психофармакотерапия. 2015; 3: 34–8. / Pribytkov A.A., Baryl'nik Iu.B., Antokhin E.Iu. i dr. Terapiia somatoformnykh rasstroistv: dannye issledovanii i povsednevnaia praktika. Psychiatry and Psychopharmacotherapy. 2015; 3: 34–8. [in Russian] 41. Прибытков А.А. Эффективность бензодиазепинов и низкопотентных антипсихотиков в качестве адъювантной терапии соматоформных расстройств. Журн. неврологии и психиатрии им. С.С.Корсакова. 2016; 5: 52–6. / Pribytkov A.A. Effektivnost' benzodiazepinov i nizkopotentnykh antipsikhotikov v kachestve ad"iuvantnoi terapii somatoformnykh rasstroistv. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2016; 5: 52–6. [in Russian] 42. Акарачкова Е.С. К вопросу диагностики и лечения психовегетативных расстройств в общесоматической практике. Лечащий врач. 2010; 10: 60–5. / Akarachkova E.S. K voprosu diagnostiki i lecheniia psikhovegetativnykh rasstroistv v obshchesomaticheskoi praktike. Lechashchii vrach. 2010; 10: 60–5. [in Russian] 43. Решетова Т.В. Нарушения вегетативной нервной системы в общей врачебной практике и их лечение. Атмосфера. Нервные болезни. 2008; 4: 6–8. / Reshetova T.V. Narusheniia vegetativnoi nervnoi sistemy v obshchei vrachebnoi praktike i ikh lechenie. Atmosfera. Nervnye bolezni. 2008; 4: 6–8. [in Russian] 44. Прибытков А.А., Орлова Е.А. Психосоматические расстройства с проявлениями в виде уртикарной сыпи. Психические расстройства в общей медицине. 2014; 2: 47–53. / Pribytkov A.A., Orlova E.A. Psikhosomaticheskie rasstroistva s proiavleniiami v vide urtikarnoi sypi. Mental Disorders in General Medicine. 2014; 2: 47–53. [in Russian] 45. Maina G, Vitalucci A, Gandolfo S, Bogetto F. Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study. J Clin Psychiatry 2002; 63 (1): 38–43. 46. Calandre EP, Rico-Villademoros F. The role of antipsychotics in the management of fibromyalgia. CNS Drugs 2012; 26 (2): 135–53. 47. Seidel S, Aigner M, Ossege M et al. Antipsychotics for acute and chronic pain in adults. Cochrane Database Syst Rev 2013; 8: CD004844. 48. Uçeyler N, Sommer C, Walitt B, Häuser W. Anticonvulsants for fibromyalgia. Cochrane Database Syst Rev 2013; 10: CD010782. 49. Houghton LA, Fell C, Whorwell PJ et al. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 2007; 56 (9): 1218–25. 50. Lee KJ, Kim JH, Cho SW. Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2005; 22 (10): 981–8. 51. García-Campayo J, Sanz-Carrillo C. Topiramate as a treatment for pain in multisomatoform disorder patients: an open trial. Gen Hosp Psychiatry 2002; 24 (6): 417–21. 52. Прибытков А.А., Савельев В.П., Юркова И.О. и др. Оценка эффективности прегабалина и флувоксамина в терапии соматоформных расстройств. Обозрение психиатрии и медицинской психологии им. В.М.Бехтерева. 2015; 4: 77–82. / Pribytkov A.A., Savel'ev V.P., Iurkova I.O. i dr. Otsenka effektivnosti pregabalina i fluvoksamina v terapii somatoformnykh rasstroistv. Obozrenie psikhiatrii i meditsinskoi psikhologii im. V.M.Bekhtereva. 2015; 4: 77–82. [in Russian] 53. Bass C, Peveler R, House A. Somatoform disorders: severe psychiatric illnesses neglected by psychiatrists. Br J Psychiatry 2001; 179: 11–4. 54. Creed F. Should general psychiatry ignore somatization and hypochondriasis? World Psychiatry 2006; 5 (3): 146–50. 55. Devulapalli KK, Nasrallah HA. An analysis of the high psychotropic off-label use in psychiatric disorders. Asian J Psychiatr 2009; 2 (1): 29–36. 56. Löwe B, Spitzer RL, Williams JB et al. Depression, anxiety and somatization in primary care: syndrome overlap and functional impairment. Gen Hosp Psychiatry 2008; 30 (3): 191–9. 57. Simon GE. Are somatoform disorders a distinct category? In: Maj M, Akiskal HS, Mezzich JE et al, editors. Somatoform disorders. Chichester: Wiley, 2005; p. 29–31. 58. Hausteiner-Wiehle C, Schäfert R, Sattel H et al. New Guidelines on Functional and Somatoform Disorders. Psychother. Psychosom Med Psychol 2013; 63 (1): 26–31. 59. Oyama O, Paltoo C, Greengold J. Somatoform disorders. Am Fam Physician 2007; 76 (9): 1333–8. 60. Somatisch Onvoldoende verklaarde Lichamelijke Klachten (SOLK) en Somatoforme Stoornissen. Utrecht: Trimbos-instituut, 2010. 61. Fink P, Burton C, de Bie J et al. Current state of management and organization of care. In: Creed F, Henningsen P, Fink P, ed. Medically unexplained symptoms, somatisation and bodily distress: developing better clinical services. Cambridge: Cambridge University Press, 2011; p. 97–124. 62. Sumathipala A. What is the evidence for the efficacy of treatments for somatoform disorders? A critical review of previous intervention studies. Psychosom Med 2007; 69 (9): 889–900. 63. Mundt A, Ströhle A, Heimann H. Pharmacoepidemiology of patients hospitalized for somatoform disorders in psychiatric hospitals and departments. Pharmacoepidemiol Drug Saf 2010; 19 (7): 687–93.